Navigation Links
Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
Date:8/1/2008

NEW BRUNSWICK, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that Bayer CropScience has successfully completed the first R&D milestone related to Bayer's use of Senesco's technology in Brassica oilseeds.

Senesco's proprietary gene technology was licensed to Bayer CropScience in November 2006 to enhance Canola yields in Bayer's InVigor(R) canola hybrids and future hybrid's business internationally. Upon completion of this milestone, Senesco received an undisclosed payment from Bayer.

"We are pleased to arrive at this initial R&D milestone with Bayer CropScience," said Bruce Galton, President and CEO of Senesco. "We believe that our gene technology has broad application to both food and non-food crops."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
2. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
3. Senesco Technologies to Present at BIO 2008 Business Forum
4. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
5. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
6. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
8. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
9. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
10. Local officials move toward monitoring nanotechnologies
11. VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... to present at 2008 BIO CEO & Investor conference at ... New York on Tuesday, February 12 at 1:15 PM (Eastern), ... -- James A. Bianco, M.D., President and CEO of Cell,Therapeutics, ... overview of,the Company,s sales and marketing strategy intended to grow ...
... eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), ... and interpretation services including,expert consultation and a ... capture and electronic patient reported outcomes,solutions), announced ... fourth quarter,results for the period ended December ...
... CHICAGO, Feb. 11 Advanced Life Sciences,Holdings, Inc. ... in the,discovery, development and commercialization of novel drugs ... diseases today,announced that it will host a conference ... and full-year financial results on Tuesday,February 19 at ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 2Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 3Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 4Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 5eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 3
(Date:8/19/2014)... German . , , ... of plants can switch off individual genes and study ... Planck Institute for Plant Breeding Research in Cologne and ... different approach. They identify small molecules that block specific ... prevent the downstream reactions. In their search for these ...
(Date:8/19/2014)... young have bigger brains than counterparts that don,t care ... study. , Stickleback fish are well known in the ... the species, rather than the female, cares for offspring. ... researchers wanted to find out if the difference in ... , In the study, published recently in Ecology ...
(Date:8/18/2014)... Ariz. Half of the Earth,s land mass is ... yet they are being transformed at an alarming rate. ... in and taking over, leading to a loss of ... ability of ecosystems to produce food specifically meat. ... Life Sciences led an investigation that quantified this loss ...
Breaking Biology News(10 mins):Researchers block plant hormone 2Researchers block plant hormone 3Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3
... N.Y. Proteins are critically important to life and the ... in nature, and there is much we still don,t know ... the stability of enzymes, a particular type of protein that ... natural environment in the cell or body, enzymes can quickly ...
... that nanoparticles, which are now present in everything from ... irreparably damaging effects on soil systems and the environment. ... every year, including silver nanoparticles which are popular as ... Department of Biology. "We started to wonder what the ...
... (April 6, 2011) -- A new drug delivery device ... Peter Rentzepis promises to unlock the potential of photosensitive ... as well. Photosensitive chemicals are molecules that ... These radicals are very active chemically, and can rip ...
Cached Biology News:Nano fit-ness: Helping enzymes stay active and keep in shape 2Common nanoparticles found to be highly toxic to Arctic ecosystem 2New device promises safer way to deliver powerful drugs 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
... Immunogen: Peptide corresponding ... human, mouse, and rat phospho-FAK (Ser843) ... NM_153831 Quality ... Molecular Weight: ...
Biology Products: